The Pharmaceutical Journal
Vol 272 No 7290 p312
13 March 2004

This article
Reprint
Photocopy

News summary

Related websites
New England Journal of Medicine abstract (more)

New breast cancer treatment

Exemestane, a new aromatase inhibitor, has shown promise in primary breast cancer. A trial suggests patients should be switched to the drug after two to three years of tamoxifen therapy (New England Journal of Medicine 2004;350:1081).